BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

```
  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
  *                                                               *
  *          Welcome to MESSENGER at USPTO                        *
  *                                                               *
  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
  *    The USPTO production files are current through:            *
  *     18 JAN 1994 for U.S. Patent Text Data.                    *
  *     18 JAN 1994 for U.S. Current Classification data.         *
  *     18 JAN 1994 for U.S. Patent Image Data.                   *
  *                                                               *
  *                                                               *
  *       * PLEASE USE 305-9000 FOR NEW TELEPHONE NUMBER *        *
  *                                                               *
  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
  *  DISCLAIMER:                                                  *
  *  Neither the United States Government, nor any agency         *
  *  thereof, nor any of their contractors, subcontractors or     *
  *  employees make any warranty, expressed or implied,           *
  *  including any warranty of marketability of fitness for a     *
  *  particular purpose; nor assumes any legal liability or       *
  *  responsibility for any party's use, or the results of        *
  *  such, of the data.                                           *
  *                                                               *
  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
  *    There is a new number to call for APS help: 305-9000.      *
  *    The Help Desk staff at this number will handle all APS     *
  *    related questions. Current hours are 6:30 am to 9:00 pm    *
  *    Monday through Friday and 7:30 am to 5:00 pm Saturday.     *
  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
  *    HOURS TO ACCESS MESSENGER ARE 6:30 AM to 9:00 PM           *
  *    MONDAY THRU FRIDAY AND 7:30 AM to 5:00 PM SATURDAY.        *
  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
FILE 'USPAT' ENTERED AT 14:32:53 ON 21 JAN 94
  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
  *               W E L C O M E   T O   T H E                   *
  *         U. S.   P A T E N T   T E X T   F I L E             *
  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
=> s (antivenin or venom?) and (fab or ( (f)(W)(ab))
UNMATCHED LEFT PARENTHESIS 'AND (FAB'
=> s (antivenin or venom?) and (fab or ( (f)(W)(ab)))
             4 ANTIVENIN
           890 VENOM?

          3238 FAB
        524985 F
         18918 AB
          1075 (F)(W)(AB)
L1          80 (ANTIVENIN OR VENOM?) AND (FAB OR ( (F)(W)(AB)))
=> t l1 cit 1-80

1.  5,279,956, Jan. 18, 1994, Activated protein C polypeptides and
anti-peptide antibodies, diagnostic methods and systems for inhibiting
activated protein C; John H. Griffin, et al., 435/183; 424/85.8;
435/69.2, 70.21, 240.27; 436/536; 514/12; 530/300, 324, 326, 328, 381,
382, 383, 384, 388.25, 388.26, 389.3, 412 [IMAGE AVAILABLE]

2.  5,279,937, Jan. 18, 1994, Use of macroglobulins to improve the
signal-to-background ratio in affinity binding assays; Gerald E. Rowe,
435/6, 7.92, 7.93, 23, 971; 436/538 [IMAGE AVAILABLE]
```

3. 5,278,144, Jan. 11, 1994, Antithrombosis agents; David Wolf, 514/12; 424/94.64; 435/69.1, 69.2, 69.6; 514/2, 8; 530/384, 395 [IMAGE AVAILABLE]

4. 5,278,064, Jan. 11, 1994, Amycolatopsis mediterranei strains useful to prepare A87689 compounds; Dennis R. Berry, et al., 435/252.1; 424/122; 435/195, 253.2, 253.5 [IMAGE AVAILABLE]

5. 5,273,885, Dec. 28, 1993, Conjugates of monophenyl thyroid analogs useful in assays; Jill M. Visor, et al., 435/7.93, 7.9, 975 [IMAGE AVAILABLE]

6. 5,270,170, Dec. 14, 1993, Peptide library and screening method; Peter J. Schatz, et al., 435/7.37, 252.33, 320.1; 935/11 [IMAGE AVAILABLE]

7. 5,260,427, Nov. 9, 1993, Nucleosidylphosphite-borane compounds and method of making the same; Bernard F. Spielvogel, et al., 536/17.1; 435/91.5; 558/72; 562/11 [IMAGE AVAILABLE]

8. 5,256,642, Oct. 26, 1993, Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof; Douglas T. Fearon, et al., 514/8; 424/94.63, 94.64; 435/215, 216; 514/2; 530/350 [IMAGE AVAILABLE]

9. 5,252,712, Oct. 12, 1993, Purified antibodies which specifically bind human abnormal prothrombin; Bruce E. Furie, et al., 530/389.3; 435/240.27; 530/388.25 [IMAGE AVAILABLE]

10. 5,246,968, Sep. 21, 1993, Glutamate receptor inhibitor; Terumi Nakajima, et al., 514/616; 564/153 [IMAGE AVAILABLE]

11. 5,242,945, Sep. 7, 1993, Tetronic and thiotetronic acid derivatives as phospholipase A.sub.2 inhibitors; Craig E. Caufield, et al., 514/473, 445, 826; 549/64, 65, 313, 314, 316, 317 [IMAGE AVAILABLE]

12. 5,242,810, Sep. 7, 1993, Bifunctional inhibitors of thrombin and platelet activation; John M. Maraganore, et al., 435/69.2, 69.6, 69.7, 172.3, 214, 252.3, 252.33, 320.1; 530/324, 856; 536/23.1, 23.4, 23.5; 930/250 [IMAGE AVAILABLE]

13. 5,229,516, Jul. 20, 1993, Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase; John H. Musser, et al., 546/172, 152, 174, 175, 176, 180 [IMAGE AVAILABLE]

14. 5,229,500, Jul. 20, 1993, Brain derived neurotrophic factor; Yves-Alain Barde, et al., 530/399; 424/88; 435/69.1; 530/350, 387.9, 389.2, 412, 413 [IMAGE AVAILABLE]

15. 5,227,469, Jul. 13, 1993, Platelet aggregation inhibitors from the leech; Robert A. Lazarus, et al., 530/324, 326 [IMAGE AVAILABLE]

16. 5,227,397, Jul. 13, 1993, Polyamines and polypeptides useful as antagonists of excitatory amino acid neuro-transmitters and/or as blockers of calcium channels; Nicholas A. Saccomano, et al., 514/419, 12; 548/495 [IMAGE AVAILABLE]

17. 5,225,571, Jul. 6, 1993, Substituted dihydroxy-bis-[5-hydroxy-2(5H)-furanone-4-yl]-alkanes as anti-inflammatory agents; Gary C. M. Lee, 549/222, 313 [IMAGE AVAILABLE]

US 5,xxx,xxx, xxx. 30, 1xxx, xxxxxxx xxxxxxxx xx xxxx xxxxxx
xxxxxxxx, xxxxxx xx xxxxx, xx xxx., xxx/xxx, xxxx, xxxx, xxxx, xxxx,
xxx/xxx, xxx/x [xxxxx xxxxxxxx]

US 5,xxx,xxx, xxx. 3, 1xxx, xxxxxxxxx xxxxxxxxxxxxxx, xxx xx
xxxxxxxx, xx xxx., xxx/xxxx, xxxx, xxxx, xxxx, xxx/xx [xxxxx
xxxxxxxx]

US 5,xxx,xxx, xxx. 3, 1xxx, xxxxxxx xxx xxxxxx xxxxxxxx xx
xxxxxxx xxx xxxxx xxxxxxxxxx xxx xxx, xxxxx xxxxxx, xxx/xx, xxx, xxxx,
xxx, xxx, xxx/xxxx [xxxxx xxxxxxxx]

US 5,xxx,xxx, xxx. 22, 1xxx, xxxxxx xx xxxxxxx xxxxxxxx x xxxxxx
xxxxx xxxxxx, xxxxx x. xxxxxxx, xx xxx., xxx/xx, xxx/xxx, xxxxx,
xxx/xxx [xxxxx xxxxxxxx]

US 5,xxx,xxx, xxx. 10, 1xxx, xxxxxxxxx xxx xxxxxxxx; xxxx
xxxxxxxxx, xx xx., xxx/xx x; xxx/xxx; xxx/xx xx [xxxxx xxxxxxxx]

US 5,xxx,xxx, xxx. 30, 1xxx, xxxxxxxxxx xx xxxxxxxx xxxxxxxxxxxx
xxxxxxxx; xxxxxx xxxxx, xx xx., xxx/xx, xx; xxx/xxx, xxx, xxx [xxxxx
xxxxxxxx]

US 5,xxx,xxx, xxx. 30, 1xxx, xxxxxxxxxxxxxx xx xxxxxxx xxxxxxxxxx
xxxxxxxx; xxxxx x. xxxxxxx, xxx/xxx, x xx; xxx/xxx, xxx, xxx [xxxxx
xxxxxxxx]

US 5,xxx,xxx, xxx. 3, 1xxx, xxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxxxx
xxxxxx xxxxxxx xxxxx; xxxxxxx xxxxxxxx, xx xx., xxx/xxx, xx x, xx x;
xxx/xxx, xxx, xxx/xxx [xxxxx xxxxxxxx]

US 5,xxx,xxx, xxx. 3, 1xxx, xxxxxxxxxxxxxx xxxxxxxxx xxxxxxxxxx
xxxxxxxxx xxxxx xxxx xxxxxxxxxxxxxx xxxxxxxxxx; xxxxxx x.
xxxxxxxxx xxxxx xxxx xxxxxxxxxxxxxx xxxxxxxxxx; xxxxxxx x.
xxxxxxxxx, xx xx., xxx/xxx; xxx/xxx, xxx [xxxxx xxxxxxxx]

US 5,xxx,xxx, xxx. 10, 1xxx, xxxxx xxxxxx xxxxxxxxxxx xxxxxx;
xxxx xxxxx xxxxx, xx xx., xxx/xx xx; xxx/xx x, xx x, xxx x;
xxx/xxx, xxx [xxxxx xxxxxxxx]

US 5,xxx,xxx, xxx. 22, 1xxx, xxxxx xxxxxx xxxxxxxxxxx xxxxxx;
xxxxx x. xxxxxxxxxxx, xx xx., xxx/xx

US 5,xxx,xxx, xxx. 3, 1xxx, xx (x xxxxxxx x(xxx),x xxx x
xxxxx(xxxxxxx xxxxx,xxxxx xxxxxxxxxxxx xxx x',x' xxx (x xxxxxxx x(xxx),x
xxx x xxxxx(xxxxxxx xxxxx,xxxxx xxxxxxxxxxxx xxx xxxxx xx
xxx x xxxxx(xxxxxxx xxxxx,xxxxx xxxxxxxxxxxx xxx xxxxx xx
xxxx xxxxxxxxxxx xxxxx; xxxx x. x. xxx, xxx/xxx, xxx [xxxxx xxxxxxxx]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

40. [illegible] [IMAGE AVAILABLE]

41. [illegible], May [illegible], 1992, Enzyme [illegible] system; [illegible], et al., [illegible] [IMAGE AVAILABLE]

42. [illegible], Feb. [illegible], 1992, Erythrocyte agglutination assay; [illegible], et al., [illegible] [IMAGE AVAILABLE]

43. [illegible], Jan. [illegible], 1992, [illegible] furanones and [illegible] furanones as anti-inflammatory agents; Gary C. M. Lee, [illegible] [IMAGE AVAILABLE]

44. 5,071,835, Dec. 10, 1991, Ribonucleotide reductase inhibitors; Yvan Guindon, et al., 514/13, 15, 17, 18, 19; 530/326, 327, 328, 329 [IMAGE AVAILABLE]

45. 5,066,789, Nov. 19, 1991, Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages; Ananthachari Srinivasan, et al., 530/391.5, 363, 391.9 [IMAGE AVAILABLE]

46. 5,066,671, Nov. 19, 1991, Ellagic acid derivatives as phospholipase A.sub.2 inhibitors; Craig E. Caufield, 514/453 [IMAGE AVAILABLE]

47. 5,066,593, Nov. 19, 1991, Synthetic peptide-based anti-rabies

[illegible]

[illegible]

[illegible]

[illegible]

[illegible] thereof; Jean-Marie Saint-Remy, et al., [illegible] [IMAGE AVAILABLE]

52. 5,021,576, Jun. 4, 1991, 2-Amino phenylacetic acid derivatives; Amedeo A. Failli, et al., 546/174, 175 [IMAGE AVAILABLE]

53. 5,013,830, May 7, 1991, Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers; Eiko Ohtsuka, et al., 536/25.1, 23.1, 25.3, 25.34, 26.7, 26.72, 26.8, 27.63, 27.81, 28.5, 28.53 [IMAGE AVAILABLE]

54. 5,001,056, Mar. 19, 1991, Preparation of monoclonal antibodies; Solomon H. Snyder, et al., 435/70.21, 172.2, 173.6, 240.27; 935/93 [IMAGE AVAILABLE]

55. 4,960,712, Oct. 2, 1990, System and method for complement pathway analysis; Argyrios N. Theofilopoulos, et al., 436/501; 435/965, 973; 436/507, 512, 536, 539, 548, 804, 821 [IMAGE AVAILABLE]

56. 4,946,788, Aug. 7, 1990, Purified immunoglobulin-related factor, novel monoclonal antibodies, hybridoma cell lines, processes and applications; Guy Delespesse, 530/388.22; 424/85.8; 435/7.5, 70.21, 172.2, 188, 240.27, 948, 961; 530/388.73, 391.3, 862, 866, 868; 935/95, 100, 102, 103, 104, 106, 107, 108, 110 [IMAGE AVAILABLE]

57. 4,939,240, Jul. 3, 1990, Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy; Tsann M. Chu, et al., 530/388.85; 424/1.1, 85.8, 85.91; 435/70.21, 188, 240.27; 530/391.3, 391.7, 808, 809; 935/104, 107 [IMAGE AVAILABLE]

58. 4,880,817, Nov. 14, 1989, O-functionalized derivatives of substituted isoquinolin-3-ols having cardiotonic and/or phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties; Ramesh M. Kanojia, et al., 514/309, 210, 235.2, 253; 544/128, 363; 546/141 [IMAGE AVAILABLE]

59. 4,876,190, Oct. 24, 1989, Peridinin-chlorophyll complex as fluorescent label; Diether J. Recktenwald, 435/7.2, 7.21, 7.23, 7.24, 968; 436/513, 537, 546, 800; 530/802 [IMAGE AVAILABLE]

60. 4,867,973, Sep. 19, 1989, Antibody-therapeutic agent conjugates; John W. F. Goers, et al., 424/85.91, 85.8, 86, 87; 514/2, 6, 8; 530/388.7, 388.9, 391.9, 828, 864, 866; 930/10, 22 [IMAGE AVAILABLE]

61. [illegible]

62. [illegible]

63. [illegible]

64. [illegible]

65. [illegible]

66. [illegible]

67. [illegible]

68. 4,707,356, Nov. 17, 1987, Synthetic peptide-based anti-rabies compositions and methods; James W. Patrick, et al., 424/88; 930/10, 220 [IMAGE AVAILABLE]

69. 4,675,287, Jun. 23, 1987, Monoclonal antibody directed to human ganglioside GD.sub.2; Ralph A. Reisfeld, et al., 435/7.23; 424/85.8, 85.91; 435/7.92, 70.21, 172.2, 240.27, 948, 975; 436/518, 528, 548, 813; 530/387.5, 388.2, 388.85, 391.3, 808, 809, 866; 935/89, 95, 106, 107 [IMAGE AVAILABLE]

70. 4,672,044, Jun. 9, 1987, Murine monoclonal antibody combining site to human C3b receptor (CR1); Robert D. Schreiber, 436/501; 435/4, 7.21, 7.24, 7.25, 70.21, 172.2, 240.27, 810, 968, 975; 436/504, 506, 507, 512, 518, 536, 540, 548, 815, 821; 935/104, 110 [IMAGE AVAILABLE]

71. 4,671,958, Jun. 9, 1987, Antibody conjugates for the delivery of compounds to target sites; John D. Rodwell, et al., 424/85.91, 1.1, 85.8, 86, 87; 514/2, 6, 8; 530/390.6, 391.5, 391.9, 828, 864, 866 [IMAGE AVAILABLE]

72. 4,661,347, Apr. 28, 1987, Cytotoxic compositions; Hans J. Muller-Eberhard, et al., 424/85.91; 435/188; 530/388.85, 391.7, 391.9, 395, 402, 403, 404, 408 [IMAGE AVAILABLE]

73. 4,652,629, Mar. 24, 1987, Synthetic peptide-based anti-rabies compositions and methods; James W. Patrick, et al., 530/326, 327, 328, 329, 330, 403; 930/10, 220 [IMAGE AVAILABLE]

74. 4,642,284, Feb. 10, 1987, Method and system for detection of complement pathway activation; Neil Cooper, et al., 435/7.94, 4, 7.4, 28,

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

(Item 1 from file: 155)
04954594 83187594
Simplified preparation of rabbit Fab fragments.
Coulter A; Harris R
J Immunol Methods Apr 29 1983, 59 (2) p199-203, ISSN 0022-1759
Journal Code: IFE
Languages: ENGLISH
Document type: JOURNAL ARTICLE
JOURNAL ANNOUNCEMENT: 8308
Subfile: INDEX MEDICUS
Papain attached to solid-phase CH-Sepharose 4B was used to digest rabbit IgG. Protein A-Sepharose CL-4B was used to remove undigested IgG and Fc fragments. Pure Fab fragments free of IgG, Fc fragments and papain were readily obtained by this procedure with a yield of about 75%. Polyacrylamide gel electrophoresis of the Fab in the presence of sodium dodecyl sulphate gave a single band under both reducing and non-reducing conditions. The molecular weight of the Fab determined by sedimentation equilibrium was 49,200. Unlike the IgG, the Fab obtained did not form precipitin lines when used in immunoelectrophoresis.
Tags: Animal
Descriptors: *Immunoglobulins, Fab--Isolation and Purification--IP; Chromatography, Ion Exchange; Electrophoresis, Polyacrylamide Gel; IgG --Analysis--AN; Immunoenzyme Techniques; Immunoglobulins, Fab--Analysis--AN ; Mice; Molecular Weight; Neurotoxins--Immunology--IM; Rabbits; Snake Venoms--Immunology--IM
CAS Registry No.: 0 (Immunoglobulins, Fab); 0 (Neurotoxins); 0 (Snake Venoms)

(6)